Daily Ards Research Analysis
Analyzed 9 papers and selected 3 impactful papers.
Summary
Analyzed 9 papers and selected 3 impactful articles.
Selected Articles
1. Prenatal prediction of neonatal respiratory distress syndrome using uteroplacental Doppler and placental microvascular perfusion indices: development of a risk model.
This retrospective study (n=362) combined uterine artery resistance (UtA-PI), cerebroplacental ratio (CPR), and placental microvascular perfusion (VFI) from 3D power Doppler to build a nomogram predicting NRDS. The model showed good discrimination and internal validation by bootstrap; authors propose clinical use for delivery planning and perinatal monitoring.
Impact: Provides a physiologically grounded, validated antenatal risk model for NRDS that could change perinatal decision-making and targeted surveillance.
Clinical Implications: If externally validated, the nomogram could guide timing of delivery, antenatal corticosteroid strategies, and preparation for neonatal respiratory support by identifying high-risk pregnancies before term.
Key Findings
- A multivariable model combining UtA-PI, CPR and placental VFI predicted NRDS in mid-pregnancy.
- Study included 362 pregnancies (NRDS n=58) with bootstrap internal validation of the nomogram.
- Authors propose the nomogram to assist delivery planning and perinatal monitoring.
Methodological Strengths
- Integration of macro- and microcirculatory Doppler indices with maternal factors
- Internal validation using bootstrap resampling and multivariable modeling
Limitations
- Retrospective, single-center design limits external generalizability
- Nomogram lacks external validation and prospective assessment of clinical utility
Future Directions: External multicenter validation, prospective testing of the nomogram's effect on delivery planning and neonatal outcomes, and integration with other biomarkers (e.g., biochemical placental markers).
BACKGROUND: Neonatal respiratory distress syndrome (NRDS) is a leading cause of neonatal morbidity and mortality; however, current antenatal risk assessments lack physiological specificity. This study aimed to evaluate the early predictive value of mid-pregnancy placental perfusion indices derived from three-dimensional power Doppler (3D-PD) imaging-the vascularization index (VI), flow index (FI), and vascularization flow index (VFI)-together with conventional Doppler parameters [e.g., the uterine artery pulsatility index (UtA-PI), cerebroplacental ratio (CPR)] and maternal clinical factors for NRDS, and to develop and validate a nomogram for individualized risk stratification. METHODS: In this retrospective study, pregnant women who underwent second-trimester ultrasound at a tertiary hospital in Xiangyang between January 2021 and December 2024 and had traceable delivery outcomes were screened (n=610). After applying the exclusion criteria, 362 women were included in the study (NRDS group, n=58; control group, n=304). Maternal variables and UtA-PI, umbilical artery PI (UA-PI), middle cerebral artery PI (MCA-PI), and CPR were collected; VI, FI, and VFI were computed offline after placental volume acquisition. The primary outcome was NRDS, defined as the need for ≥24 hours of oxygen/respiratory support and neonatal intensive care unit (NICU) admission. Univariate and multivariate logistic regression analyses were performed to identify independent predictors; a nomogram was constructed from the final model. Discrimination, calibration, and clinical utility were assessed using receiver operating characteristic (ROC) analysis, calibration curves, and decision curve analysis (DCA), with internal validation by bootstrap resampling. RESULTS: Compared with the control group, the NRDS group showed higher UtA-PI (1.15±0.38 CONCLUSIONS: Integrating uteroplacental macrocirculatory resistance (UtA-PI and CPR) with microcirculatory perfusion (VFI) and key maternal factors enables effective early risk stratification for NRDS. The proposed nomogram is intuitive and practical, exhibits good discriminatory performance, and may guide delivery planning, perinatal monitoring, and timely intervention.
2. The relationship between the chronological phases of diffuse alveolar damage and clinical outcomes in acute respiratory distress syndrome.
Retrospective histology-linked study of 90 ARDS patients who underwent lung biopsy found that rapid progression of DAD (proliferative phase ≤7 days or fibrotic phase ≤21 days) was independently associated with higher 60-day mortality (HR 2.274). Absolute phase (proliferative vs fibrotic) alone did not predict mortality, but the tempo of progression did.
Impact: Links histopathologic tempo of alveolar damage to clinically meaningful outcomes, suggesting dynamics of lung injury (not just phase) should inform prognosis and potentially timing of interventions.
Clinical Implications: Histologic rapid progression could identify patients at high risk who may benefit from early, aggressive supportive or targeted therapies; consideration for earlier escalation or enrollment in clinical trials for rapidly progressive DAD.
Key Findings
- Among 90 biopsy-confirmed ARDS patients, rapid progression of DAD (predefined time thresholds) was associated with higher 28- and 60-day mortality.
- Rapid progression was an independent predictor of 60-day mortality (HR 2.274; p=0.014).
- Absolute histologic phase (proliferative vs fibrotic) without consideration of timing did not significantly predict mortality.
Methodological Strengths
- Histologically confirmed DAD using open lung biopsy and cryobiopsy increases pathological specificity
- Predefined temporal criteria for 'rapid progression' and multivariable survival analysis
Limitations
- Retrospective design and potential selection bias (biopsy performed in selected patients)
- Moderate sample size (n=90) and incomplete reporting of some physiologic variables in abstract
Future Directions: Prospective studies to validate temporal thresholds, incorporation of serial imaging/biomarkers to noninvasively track DAD progression, and trials testing earlier targeted therapies in rapid progressors.
BACKGROUND: Diffuse alveolar damage (DAD) represents the hallmark histopathological feature of acute respiratory distress syndrome (ARDS); however, its prognostic significance remains unclear. This study aimed to evaluate the associations between the chronological phases of histologically confirmed DAD and clinical outcomes in patients with ARDS. METHODS: In this retrospective study, we included patients diagnosed with ARDS who underwent open lung biopsy between January 2002 and December 2025 or transbronchial lung cryobiopsy between January 2017 and December 2025. Rapid progression was defined as the presence of the proliferative phase within 7 days or the fibrotic phase within 21 days from ARDS diagnosis to lung biopsy. RESULTS: A total of 90 patients were included in the analysis. No significant differences were observed in 28-day mortality (36.5% vs. 43.5%, p = 0.556) or 60-day mortality (63.5% vs. 69.9%, p = 0.601) between patients in the proliferative and fibrotic phases. In contrast, patients with rapid progression demonstrated significantly higher 28-day mortality (47.9% vs. 23.8%, p = 0.018) and 60-day mortality (72.9% vs. 50.0%, p = 0.025) than those without rapid progression. Multivariable analysis identified rapid progression as an independent predictor of 60-day mortality (hazard ratio, 2.274; p = 0.014). Furthermore, patients with rapid progression had significantly lower PaCO CONCLUSION: Rapid progression of DAD was associated with significantly poorer clinical outcomes, and patients with rapid progression had significantly lower PaCO
3. Immunometabolic reprogramming and mitochondrial dysfunction in acute respiratory distress syndrome: mechanisms, metabolic resilience, and therapeutic perspectives- a narrative review.
Narrative review synthesizing preclinical and clinical evidence that immunometabolic reprogramming (increased glycolysis, impaired oxidative phosphorylation) and mitochondrial dysfunction underpin ARDS heterogeneity. Proposes metabolic resilience as a framework and highlights therapeutic targets (mitochondrial support, NAD+ restoration, metabolite signalling modulation).
Impact: Frames ARDS heterogeneity around actionable metabolic pathways and mitochondrial function, providing conceptual guidance for biomarker-driven phenotyping and metabolism-targeted interventions.
Clinical Implications: Encourages incorporation of metabolic phenotyping (multi-omics, metabolomics) into ARDS stratification and supports clinical trials targeting mitochondrial function or NAD+ metabolism in selected phenotypes.
Key Findings
- Immunometabolic reprogramming (↑glycolysis, ↓OXPHOS) is a consistent feature in injured immune and structural lung cells in ARDS.
- Accumulation of metabolites (lactate, succinate, extracellular ATP) acts as signalling mediators that perpetuate inflammation and barrier injury.
- Concept of 'metabolic resilience' may explain differential recovery and identify targets (mitochondrial support, NAD+ restoration) for precision therapy.
Methodological Strengths
- Comprehensive synthesis across preclinical, multi-omic, and clinical studies providing mechanistic integration
- Clear translational focus linking mechanisms to candidate therapeutic strategies
Limitations
- Narrative (non-systematic) review susceptible to selection bias and lacking quantitative bias assessment
- Translational gaps remain: most therapeutic strategies remain preclinical or early-phase
Future Directions: Prospective cohort phenotyping with multi-omics and metabolomics, randomized trials of mitochondrial-supportive or NAD+-modulating interventions in biologically stratified ARDS subgroups, and development of bedside metabolic biomarkers.
BACKGROUND: Acute respiratory distress syndrome (ARDS) is a biologically heterogeneous condition in which patients exposed to similar injurious stimuli often develop markedly different clinical trajectories and outcomes. While inflammation is central to ARDS pathogenesis, inflammatory burden alone does not fully explain the variability in disease progression, treatment response, or recovery. Emerging evidence suggests that immunometabolic reprogramming, characterized by increased glycolysis, impaired mitochondrial oxidative phosphorylation, and altered metabolite signalling, plays a critical role in shaping immune-cell activation, inflammatory persistence, and tissue repair during critical illness. MAIN BODY: This narrative review synthesizes current evidence linking immunometabolic reprogramming and mitochondrial dysfunction to the clinical heterogeneity observed in ARDS. During acute lung injury, immune and structural lung cells undergo metabolic shifts characterized by increased glycolysis, impaired mitochondrial oxidative phosphorylation, and accumulation of bioactive metabolites such as lactate, succinate, and extracellular adenosine triphosphate (ATP). Beyond reflecting metabolic stress, these metabolites function as signalling mediators that are associated with amplified inflammatory pathways, compromised alveolar-capillary barrier integrity, and sustained lung injury. Multi-omic studies further demonstrate that distinct metabolic signatures are associated with ARDS phenotypes, disease severity, and treatment responsiveness. We integrate these findings within the concept of metabolic resilience, defined as the host's capacity to restore coordinated mitochondrial function, redox balance, and substrate utilization following inflammatory stress. Therapeutic strategies aimed at preserving mitochondrial function, restoring nicotinamide adenine dinucleotide (NAD⁺) homeostasis, and modulating maladaptive immunometabolic signalling may offer new avenues for precision-based interventions in ARDS. CONCLUSIONS: Immunometabolic reprogramming and mitochondrial dysfunction represent central biological axes linking cellular bioenergetics with clinical heterogeneity in ARDS. Understanding metabolic resilience may help refine phenotyping strategies and support development of metabolism-targeted therapies aimed at improving outcomes in this complex syndrome. CLINICAL TRIAL NUMBER: Not applicable.